A draft report from the Agency for Healthcare Research and Quality examines the research evidence relating to medication therapy management. (AHRQ Report) Medication therapy management, also sometimes referred to as pharmaceutical care, intensively focuses on the drug use of patients and identifies potential issues interfering with maximum value of drug therapies. It results in an individualized care plan for each patient and typically involves ongoing followup. CMS has required Medicare Advantage plans to engage a class of patients with high drug use or expenses in MTM and recently released a proposed rule which would greatly expand the patients for whom the MA plans should be doing MTM. The key questions addressed by the AHRQ report included describing the intervention components and implementation features, assess the effectiveness of MTM on outcomes, identify intervention features or patient characteristics that appear associated with effects on outcomes and identify any potential harms from MTM. Out of a large pool, only 36 studies met the criteria to be included in the review and most of those were considered low strength. Compared to usual care, the outcomes had low strength evidence of improving medication appropriateness, the use of generic medications and lowering the rate of hospitalization among heart failure patients. No benefit was found for most other outcomes examined, including general reduction of hospitalizations or quality of life, but again the evidence for no benefit is low strength. The authors called for a significant improvement in the research to evaluate MTM. The draft report should not be too discouraging to MTM vendors; like most AHRQ systematic reviews the problem is just a lack of good quality studies. The real-life experience of many plans deploying MTM is far more positive than the report would suggest. Properly done research will eventually catch up and validate MTM’s value.
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
May 30, 2023
The CV-19 and Vax Lies Continue
Three pieces of misleading research or at least reporting of research indicate why science is…
Commentary
May 29, 2023
Expect More of This
Minnesota's suicide rate has risen by 40% in twenty years. Democrats have been in charge…
Commentary
May 29, 2023
Some Quick Climate News
CO2 and temperature have a complex relationship and the Arctic isn't going through unprecendented warmth.
I suspect that what from a distance appears to be a generic grouping of MTM providers, closer inspection will show a heterogeneity of approaches and efficacies. A quick Medi-span check for drug interactions might qualify as MTM and in which case I am not surprised that the (albeit low strength) evidence showed little benefit. An arrestingly high proportions of hospital readmissions seem to be as a result of ‘medication issues’ so I believe that a detailed MTM review might potentially be a key tool in this regard.